RecipharmCobra Biologics and KAHR Medical Announce Continuation of Partnership in the Development of KAHR-102
News Jun 21, 2011
RecipharmCobra Biologics, and KAHR Medical Ltd., that develops novel drugs based on the Signal Converter Proteins (SCP) technology for the treatment of cancer and autoimmune diseases, have announced a continuation of their partnership agreement.
Under the terms of the agreement, RecipharmCobra Biologics will continue to advance KAHR-102 for future pre-clinical and clinical testing using RecipharmCobra’s maxXpress service.
Peter Coleman, General Manager at RecipharmCobra Biologics, said: “We are extremely pleased that our development partnership continues with KAHR. Our partnership with KAHR has strengthened over the years due to the strong working relationship between both technical teams and we look forward to its continuation. It is an endorsement of the working relationship we invest in with our customers.”
Dr. Noam Shani, CEO of KAHR Medical, said “It has been a pleasure working with RecipharmCobra Biologics over the years and we have enjoyed the interaction and responsiveness of its team. We hope to build on our successful partnership with the fast-track development of KAHR-102.”
Using EBX reagents, researchers have converted the C-terminal carboxylic acid of peptides into a carbon-carbon triple bond - an alkyne (in chemical jargon a "decarboxylative alkynylation"). The alkyne moiety is a very valuable functional group that can be used to further modify the peptides.READ MORE